Intesa Sanpaolo Start-up Initiative - Frankfurt Biochem Accelerator Forum

Frankfurt, DE - June 21, 2012

BIOCHEM Accelerator Forum/Intesa Sanpaolo Start-Up Initiative at ACHEMA

'Laboratories' photo (c) 2011, Saint Louis University Madrid Campus - license: http://creativecommons.org/licenses/by-nd/2.0/

Intesa Sanpaolo is delighted to be partner of theVenture Capital Event of the BIOCHEM Accelerator Forum taking place on June 21, 2012 at the Frankfurter Messe, Ludwig-Erhard-Anlage 1.
The BIOCHEM Venture Capital Event is designed to provide support to entrepreneurs that are considering setting up a business in the Bio Based Business domain. The BIOCHEM Venture Capital Event is part of the BIOCHEM project, which is funded by the European Commission and supported by the Start-Up Initiative of Intesa Sanpaolo.
 
The BIOCHEM Accelerator Forum will exceptionally be held in within ACHEMA 2012, the world forum of the process industry and the trend-setting technology summit for chemical engineering, environmental protection and biotechnology. The 30th ACHEMA will again be the leading international meeting point for decision-makers and experts from all related industries.
 
We kindly ask you to respond to this invitation by writing us at startup@intesasanpaolo.com.
 
We look forward to meeting you in Frankfurt, and hope we can count with your valuable contribution for the success of the Biochem Venture Capital Event at ACHEMA (www.e-unlimited.com/biochem).

Selected Start-Ups
  • Natural innovative solutions to meet the growing demand for environmentally friendly pest management products
  • Systems for the bioconversion of organic material based on a new proprietary technology
  • The new generation of leads for neuromodulation (NM) for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
  • Our business is focused on the production of innovative supports for massive tissue regeneration and cell expansion
  • We launch a new business project: an innovative solution for stem cell sorting in cell therapy and regenerative medicine.
  • spin-off from the R&D Division of a pharma company, dealing with novel cell-based therapeutic approach against cancer